ZymIQ Biopharma
Biotechnology Research • • 1-10 Employees
Company overview
| Headquarters | XX |
| Websites | |
| NAICS | 541714 |
| Employees | 1-10 |
Key Contact at ZymIQ Biopharma
Mats Clarsund
CEO
About ZymIQ Biopharma
ZymIQ Biopharma leads the fight against antimicrobial resistance with enzyme-based and phage-derived solutions. It was formed through the acquisition of Novalysin AB and Delmont Laboratories. ZymIQ Biopharma blends expertise in phage science with advanced research in enzyme-based antibiotics. Key projects like Staphage Lysate (SPL)® and a novel tuberculosis project target global health challenges. Focused on precision antimicrobials, ZymIQ Biopharma aims to revolutionize treatment for human and animal health with targeted, effective, and safe therapies. Key Projects and Achievements: - Staphage Lysate (SPL)® A novel phage-derived therapy for staphylococcal infections, transitioning from human to veterinary use, with plans for reintroduction in human medicine. - Tuberculosis Development of an innovative enzyme-based antibiotic platform targeting drug-resistant Mycobacterium strains. Our approach is designed to improve specificity, reduce treatment time, and combat multi-drug-resistant strains of tuberculosis.
ZymIQ Biopharma revenue & valuation
| Annual revenue | $85,555 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $273,776 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
ZymIQ Biopharma has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
ZymIQ Biopharma has never raised funding before.
United States
United Kingdom
Germany
Frequently asked questions
4.8
40,000 users
